TSLA
PLTR
HIMS
SPCX
SOFI
BTCTruist raises price target, Wegovy execution progress, additional Eucalyptus data
Truist raised its HIMS price target from $18 to $23 (Hold), an increase of 27.8%. It is the first sell-side firm to raise its target since the Q1 results. The shares, at $24.01, are already above the target. HIMS has completed more than 125,000 Wegovy delivery orders and targets adding 100,000+ weight-loss subscribers a month by the end of the year.
Read more
Q2 guidance is $680-700 million. Eucalyptus's annualised revenue run rate is above $450 million, and its ARR growth exceeded 100% in every quarter of 2025. The acquisition is expected to complete in the second half of 2026 and, once consolidated, should contribute materially to the three-year target of $1 billion in international revenue. The shares have risen three days in a row to $24.01 (up 4.21%), with short-term resistance at $25.50.
Analyst revisions
- Action
raise
- Bank
Truist
- New
$23
- Old
$18
- Rating
Hold
- Action
cut
- Bank
Bank of America
- New
$28
- Old
$32
- Action
cut
- Bank
Deutsche Bank
- New
$25
- Old
$28
Key data points
- Acquisition timeline
H2 2026
- Current price
$24.01
- Eucalyptus ARR
$450M+
- Eucalyptus ARR growth
>100% QoQ in 2025
- International revenue target
$1B in 3 years
- Monthly weight-loss subscriber target
100,000+ by year-end
- Price change
+4.21% (3-day streak)
- Q2 guidance
$680M-$700M
- Rating
Hold
- Resistance
$25.50
- Truist target raise
$18 to $23 (+27.8%)
- Wegovy orders completed
125,000+
A brief is a lead for our research, not a verified conclusion or advice.